Function of Platelet Glycosphingolipid Microdomains/Lipid Rafts
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
From Genes to Systems: New Global Strategies for the Characterization of NCL Biology ⁎ Anu Jalanko A, , Jaana Tyynelä B, Leena Peltonen A,C,D,E
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1762 (2006) 934–944 www.elsevier.com/locate/bbadis Review From genes to systems: New global strategies for the characterization of NCL biology ⁎ Anu Jalanko a, , Jaana Tyynelä b, Leena Peltonen a,c,d,e a National Public Health Institute, Department of Molecular Medicine, Biomedicum Helsinki, P.O. Box 104, 00251 Helsinki, Finland b University of Helsinki, Institute of Biomedicine/Biochemistry, Finland c University of Helsinki, Department of Medical Genetics, Finland d Research Programme of Molecular Medicine and Research Programme of Neurosciences, Biomedicum Helsinki, Finland e The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA Received 22 April 2006; received in revised form 1 September 2006; accepted 5 September 2006 Available online 12 September 2006 Abstract Neuronal ceroid lipofuscinoses (NCL) are rare neurological disorders with a uniform phenotype, caused by mutations in seven known genes. NCL provide a unique model to characterize molecular pathways critical for normal neuronal development and pathological neuronal degeneration. Systems biology based approach utilizes the rapidly developing tools of genomics, proteomics, lipidomics and metabolomics and aims at thorough understanding of the functions of cells, tissues and whole organisms by molecular analysis and biocomputing-assisted modeling. The systems level understanding of NCL is now possible by utilizing different model organisms. Initial work has revealed disturbed metabolic pathways in several NCL disorders and most analyses have utilized the infantile (INCL/CLN1) and juvenile (JNCL/CLN3) disease modeling and utilized mainly human and mouse samples. -
Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1. -
The Two Faces of Thrombosis: Coagulation Cascade and Platelet Aggregation. Are Platelets the Main Therapeutic Target
Thrombosis and Circulation Open Access Cimmino et al., J Thrombo Cir 2017, 3:1 Review Article Open Access The Two Faces of Thrombosis: Coagulation Cascade and Platelet Aggregation. Are Platelets the Main Therapeutic Target? Giovanni Cimmino*, Salvatore Fischetti and Paolo Golino Department of Cardio-Thoracic and Respiratory Sciences, Section of Cardiology, University of Campania “Luigi Vanvitelli”, Naples, Italy *Corresponding author: Giovanni Cimmino, MD, PhD, Department of Cardio-Thoracic and Respiratory Sciences, Section of Cardiology, University of Campania “Luigi Vanvitelli”, via Leonardo Bianchi, 180131 Naples, Italy. Tel: +39-081-7064175, Fax: +39-081-7064234; E-mail: [email protected] Received date: Dec 28, 2016, Accepted date: Jan 27, 2017, Published date: Jan 31, 2017 Copyright: © 2017 Giovanni C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Acute thrombus formation is the pathophysiological substrate underlying several clinical conditions, such as acute coronary syndrome (ACS) and stroke. Activation of coagulation cascade is a key step of the thrombotic process: vessel injury results in exposure of the glycoprotein tissue factor (TF) to the flowing blood. Once exposed, TF binds factor VII/VIIa (FVII/FVIIa) and in presence of calcium ions, it forms a tertiary complex able to activate FX to FXa, FIX to FIXa, and FVIIa itself. The final step is thrombin formation at the site of vessel injury with subsequent platelet activation, fibrinogen to fibrin conversion and ultimately thrombus formation. Platelets are the key cells in primary hemostasis. -
Steric Blockage of Lysenin Toxin by Crowding
bioRxiv preprint doi: https://doi.org/10.1101/2020.05.02.073940; this version posted May 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Steric blockage of lysenin toxin by crowding Ignacio L.B. Munguira1 & Alfonso Barbas2 1 U1006 INSERM, Université Aix-Marseille, Parc Scientifique et Technologique de Luminy, 163 avenue de Luminy, 13009 Marseille, France 2Instituto de Fusión Nuclear, José Gutiérrez Abascal 2, 28006 Madrid, Spain Abstract Increasing evidence signals the importance of macromolecular crowding on the regulation of the membrane protein activity. Lysenin is a pore forming toxin that forms crowded assemblies in membrane containing sphingomyelin microdomains. We studied the role of crowding on the activity of Lysenin thanks to High Speed Atomic Force Microscopy. In this study we show that pore formation requires available space around to take place, being sterically block in crowded environments, and verified it with non- Supported Lipid Bilayers mimicking the mechanical conditions of cell membranes. A continuous pH decrease and a single molecule compression experimentsdetails show that pore formation liberates membrane space leading to prepore-forto -pore transitions. The study of the effects of prepore insertion comparing pore formation induced by sudden pH decrease in lysenin assemblies with thousand DOIsimulations show that liberation of space unblocks pore formation and could contribute to elude the cellular non-immune defences. Based on our findings we propose a refinement of current prepore structure and insertion models. -
Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma: a Single-Centre, Observer-Blinded, Randomized Controlled Trial (Trace)
TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) by Adriana Micheline Workewych A thesis submitted in conformity with the requirements for the degree of Master of Science Institute of Medical Science University of Toronto © Copyright by Adriana Micheline Workewych 2018 TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) Adriana Micheline Workewych Master of Science Institute of Medical Science University of Toronto 2018 ABSTRACT Chronic subdural hematoma (CSDH) is a frequent consequence of head trauma, particularly in older individuals. Given the aging of populations globally, its incidence is projected to increase substantially. Hyperfibrinolysis may be central to CSDH enlargement by causing excessive clot degradation and liquefaction, impeding resorption. The only current standard treatment for CSDH is surgery, however, up to 31% of residual hematomas enlarge, requiring reoperation. Tranexamic acid (TXA), an antifibrinolytic medication that prevents excessively rapid clot breakdown, may help prevent CSDH enlargement, potentially eliminating the need for repeat surgery. To evaluate the feasibility of conducting a trial investigating TXA efficacy in residual CSDH, we conducted an observer-blinded, pilot randomized controlled trial (RCT). We showed this trial was feasible and safe, reporting only minor to moderate AEs, and an attrition rate of 4%. The results from this study will inform the conduct of a double-blinded RCT investigating TXA efficacy in post-operative CSDH management. ii ACKNOWLEDGEMENTS First, I would like to thank my supervisor Dr. Michael Cusimano, my mentor for nearly six years. You have always given me more opportunity than I could have ever hoped for – I could not ask for a more dedicated teacher. -
Glycosphingolipid Metabolism in Cell Fate Specification Domenico Russo1,*, Laura Capolupo1,2, Jaipreet Singh Loomba1,2, Lucia Sticco1 and Giovanni D’Angelo1,2,*
© 2018. Published by The Company of Biologists Ltd | Journal of Cell Science (2018) 131, jcs219204. doi:10.1242/jcs.219204 REVIEW Glycosphingolipid metabolism in cell fate specification Domenico Russo1,*, Laura Capolupo1,2, Jaipreet Singh Loomba1,2, Lucia Sticco1 and Giovanni D’Angelo1,2,* ABSTRACT anchoring. Specifically at the PM, sphingolipids participate in Glycosphingolipids (GSLs) are ubiquitous components of eukaryotic signaling events by recruiting signaling molecules to, or plasma membranes that consist of a ceramide backbone linked to a sequestering them at, membrane microdomains for the modulation glycan moiety. Both the ceramide and the glycan parts of GSLs display of their activities and for their processing into the endocytic cycle structural variations that result in a remarkable repertoire of diverse (Holthuis and Menon, 2014; Holthuis et al., 2001; Simons and compounds. This diversity of GSLs is exploited during embryogenesis, Ikonen, 1997). Given these properties, sphingolipids are proposed to when different GSLs are produced at specific developmental stages and function as fundamental membrane organizers and to make up along several differentiation trajectories. Importantly, plasma membrane the fabric of eukaryotic PMs in order to influence the interaction receptors interact with GSLsto modify their activities. Consequently, two with the extracellular environment (Hannun and Obeid, 2018; otherwise identical cells can respond differently to the same stimulus Holthuis et al., 2001). owing to their different GSL composition. The metabolic reprograming of Interestingly, different cell types exhibit a specific sphingolipid GSLs is in fact a necessary part of developmental programs, as its array at their PMs (Hakomori, 2003; Ngamukote et al., 2007) impairment results in developmental failure or tissue-specific defects. -
Path Ggf 5 2020.Pdf
Hemostasis Hemostasis and Thrombosis Normal hemostasis is a consequence of tightly regulated processes that maintain blood in a fluid state in normal vessels, yet also permit the rapid formation of a hemostatic clot at the site of a vascular injury. Thrombosis involves blood clot formation within intact vessels. Both hemostasis and thrombosis involve three components: the vascular wall, platelets and the coagulation cascade. Elements of the Hemostatic process • Endothelium • Anti-thrombosis • Pro-thrombosis • Platelets • Platelet-endothelial cell interaction • Coagulation cascade http://www.as.miami.edu/chemistry/2086/chapter_21/NEW-Chap21_class_part1_files/image002.jpg After initial injury there is a brief period of arteriolar vasoconstriction mediated by reflex neurogenic mechanisms and augmented by the local secretion of factors such as endothelin (a potent endothelium-derived vasoconstrictor) The effect is transient, however, and bleeding would resume if not for activation of the platelet and coagulation systems. Endothelial injury exposes highly thrombogenic subendothelial extracellular matrix (ECM), facilitating platelet adherence and activation. Activation of platelets results in a dramatic shape change (from small rounded discs to flat plates with markedly increased surface area), as well as the release of secretory granules. Within minutes the secreted products recruit additional platelets (aggregation) to form a hemostatic plug; this process is referred to as primary hemostasis. http://www.ouhsc.edu/platelets/Platelet%20Pic s/Platelets3.jpg http://medcell.med.yale.edu/histology/blood_bone_marr ow_lab/images/platelets_em.jpg Tissue factor is also exposed at the site of injury. Also known as factor III and thromboplastin, tissue factor is a membrane-bound procoagulant glycoprotein synthesized by endothelial cells. It acts in conjunction with factor VII (see below) as the major in vivo initiator of the coagulation cascade, eventually culminating in thrombin generation. -
Understanding the Invisible Hands of Sample Preparation for Cryo-EM
FOCUS | REVIEW ARTICLE FOCUS | REVIEWhttps://doi.org/10.1038/s41592-021-01130-6 ARTICLE Understanding the invisible hands of sample preparation for cryo-EM Giulia Weissenberger1,2,3, Rene J. M. Henderikx1,2,3 and Peter J. Peters 2 ✉ Cryo-electron microscopy (cryo-EM) is rapidly becoming an attractive method in the field of structural biology. With the exploding popularity of cryo-EM, sample preparation must evolve to prevent congestion in the workflow. The dire need for improved microscopy samples has led to a diversification of methods. This Review aims to categorize and explain the principles behind various techniques in the preparation of vitrified samples for the electron microscope. Various aspects and challenges in the workflow are discussed, from sample optimization and carriers to deposition and vitrification. Reliable and versatile specimen preparation remains a challenge, and we hope to give guidelines and posit future directions for improvement. ryo-EM is providing macromolecular structures with the optimum biochemical state of the sample. Grid preparation up to atomic resolution at an unprecedented rate. In this describes the steps needed to make a sample suitable for analysis Ctechnique, electron microscopy images of biomolecules in the microscope. These steps involve chemical or plasma treat- embedded in vitreous, glass-like ice are combined to generate ment of the grid, sample deposition and vitrification. The first three-dimensional (3D) reconstructions. The detailed structural breakthroughs came about from a manual blot-and-plunge method models obtained from these reconstructions grant insight into the developed in the 1980s15 that is still being applied to achieve formi- function of macromole cules and their role in biological processes. -
RIASTAP®, Fibrinogen Concentrate (Human) Lyophilized Powder for Solution for Intravenous Injection
HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------------------CONTRAINDICATIONS ------------------------------------ These highlights do not include all the information needed to use RIASTAP • Known anaphylactic or severe systemic reactions to human plasma-derived products (4). safely and effectively. See full prescribing information for RIASTAP. ---------------------------------WARNINGS AND PRECAUTIONS---------------------------- RIASTAP®, Fibrinogen Concentrate (Human) • Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment (5.1). Lyophilized Powder for Solution for Intravenous Injection • Thrombotic events have been reported in patients receiving RIASTAP. Weigh the benefits of administration versus the risks of thrombosis (5.2). Initial U.S. Approval: 2009 • Because RIASTAP is made from human blood, it may carry a risk of transmitting ------------------------------------RECENT MAJOR CHANGES--------------------------------- infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent Indications and Usage (1) 06/2021 and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent (5.3). Dosage and Administration (2.2) 07/2020 -------------------------------------ADVERSE REACTIONS-------------------------------------- ----------------------------------INDICATIONS AND USAGE----------------------------------- • The most serious adverse reactions observed are thrombotic episodes (pulmonary RIASTAP, Fibrinogen -
Platelet Surface Glycoproteins. Studies on Resting and Activated Platelets and Platelet Membrane Microparticles in Normal Subjec
Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J N George, … , N Kieffer, P J Newman J Clin Invest. 1986;78(2):340-348. https://doi.org/10.1172/JCI112582. Research Article The accurate definition of surface glycoprotein abnormalities in circulating platelets may provide better understanding of bleeding and thrombotic disorders. Platelet surface glycoproteins were measured on intact platelets in whole blood and platelet membrane microparticles were assayed in cell-free plasma using 125I-monoclonal antibodies. The glycoproteins (GP) studied were: GP Ib and GP IIb-IIIa, two of the major intrinsic plasma membrane glycoproteins; GMP-140, an alpha- granule membrane glycoprotein that becomes exposed on the platelet surface following secretion; and thrombospondin (TSP), an alpha-granule secreted glycoprotein that rebinds to the platelet surface. Thrombin-induced secretion in normal platelets caused the appearance of GMP-140 and TSP on the platelet surface, increased exposure of GP IIb-IIIa, and decreased antibody binding to GP Ib. Patients with adult respiratory distress syndrome had an increased concentration of GMP-140 and TSP on the surface of their platelets, demonstrating in vivo platelet secretion, but had no increase of platelet microparticles in their plasma. In contrast, patients after cardiac surgery with cardiopulmonary bypass demonstrated changes consistent with membrane fragmentation without secretion: a decreased platelet surface concentration of GP Ib and GP IIb with no increase of GMP-140 and TSP, and an increased plasma concentration of platelet membrane microparticles. These methods will help to define acquired abnormalities of platelet surface glycoproteins. -
The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation Using ADP
RESEARCH ○○○○○○○○ The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation using ADP ROBERT F CORNELL, TIM R RANDOLPH ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ OBJECTIVE: Determine the minimum concentration of plasma INDEX TERMS: ADP; aggregation; fibrinogen; platelets. fibrinogen needed to stimulate the aggregation of platelets, col- lected from normal subjects, using ADP. Clin Lab Sci 2001;15(1):30 DESIGN: Platelet rich plasmas (300 x 109 platelets/L) were made Robert F Cornell II was a student in the Department of Clinical and adjusted to final fibrinogen concentrations of 75, 19, 5, and 0 Laboratory Science, Saint Louis University Health Sciences Center, St mg/dL using fibrinogen free serum. Each fibrinogen concentra- Louis MO when this research was done. Downloaded from tion in all twelve subjects was aggregated with ADP. Tim R Randolph MS is an Assistant Professor in the Department of SETTING: Research laboratory in the Department of Clinical Clinical Laboratory Science, School of Allied Health Professions, Saint Laboratory Science at Saint Louis University. Louis University Health Sciences Center, St Louis MO. PARTICIPANTS: Twelve healthy volunteers of both genders, be- Address for correspondence: Tim R Randolph MS, Saint Louis Uni- http://hwmaint.clsjournal.ascls.org/ tween the ages of 18 and 60 years who were not pregnant and versity School of Allied Health Professions, Department of Clinical Labo- weighed at least 110 pounds were included in the study. Subjects ratory Science, Room 3096, 3437 Caroline St, St Louis MO 63104. were excluded from the study if they had ingested aspirin within (314) 577-8518, (314) 577-8503 (fax). [email protected] one week prior to blood collection. -
Biomechanical Thrombosis: the Dark Side of Force and Dawn of Mechano- Medicine
Open access Review Stroke Vasc Neurol: first published as 10.1136/svn-2019-000302 on 15 December 2019. Downloaded from Biomechanical thrombosis: the dark side of force and dawn of mechano- medicine Yunfeng Chen ,1 Lining Arnold Ju 2 To cite: Chen Y, Ju LA. ABSTRACT P2Y12 receptor antagonists (clopidogrel, pras- Biomechanical thrombosis: the Arterial thrombosis is in part contributed by excessive ugrel, ticagrelor), inhibitors of thromboxane dark side of force and dawn platelet aggregation, which can lead to blood clotting and A2 (TxA2) generation (aspirin, triflusal) or of mechano- medicine. Stroke subsequent heart attack and stroke. Platelets are sensitive & Vascular Neurology 2019;0. protease- activated receptor 1 (PAR1) antag- to the haemodynamic environment. Rapid haemodynamcis 1 doi:10.1136/svn-2019-000302 onists (vorapaxar). Increasing the dose of and disturbed blood flow, which occur in vessels with these agents, especially aspirin and clopi- growing thrombi and atherosclerotic plaques or is caused YC and LAJ contributed equally. dogrel, has been employed to dampen the by medical device implantation and intervention, promotes Received 12 November 2019 platelet thrombotic functions. However, this platelet aggregation and thrombus formation. In such 4 Accepted 14 November 2019 situations, conventional antiplatelet drugs often have also increases the risk of excessive bleeding. suboptimal efficacy and a serious side effect of excessive It has long been recognized that arterial bleeding. Investigating the mechanisms of platelet thrombosis